Skip to main content
Find more clinical trials

Glutathione for Alzheimer's Disease

Start: February 1, 2021
End: May 31, 2025
Enrollment: 52

What Is This Study About?

Research suggests that low levels of glutathione, a protective substance made in the body, may be linked to Alzheimer's disease. Glutathione levels can be increased by taking supplements of glycine and cysteine, which combine in the body to make glutathione. This clinical trial will evaluate the effects of glycine-cysteine supplements in people with Alzheimer's disease. Participants will be randomly assigned to receive supplements of either glycine-cysteine or a placebo for 24 weeks. Participants will undergo MRI and PET brain imaging scans, assessments, and tests so researchers can measure changes in cognition, glutathione levels, brain cell energy use, and brain inflammation.

Do I Qualify To Participate in This Study?

Minimum Age: 55 Years

Maximum Age: 85 Years

Must have:

  • Gradual and progressive memory loss for more than one year
  • Montreal Cognitive Assessment score of 10 to 20
  • Presence of tau deposits in brain based on a PET brain imaging scan 
  • Availability of a study partner

Must NOT have:

  • Hospitalization in past three months
  • Known diabetes or use of anti-diabetic medications
  • Known kidney or liver disease
  • Untreated thyroid disease
  • History of stroke, brain tumor, active heart failure, or active cancer (removable basal cell cancers are allowed)
  • Untreated depression or other severe psychiatric disorders
  • Pregnancy or nursing

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Rajagopal V Sekhar, M.D.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Texas
Baylor College of Medicine
Houston, TX 77030
Recruiting
Rajagopal V Sekhar, MD

Who Sponsors This Study?

Lead: Baylor College of Medicine

Collaborator Sponsor

  • Nantz National Alzheimer's Center, Methodist Hospital, Houston, TX

Source: ClinicalTrials.gov ID: NCT04740580